Get the Stockscreener App
4.57
7.53%
0.32
Pre-market:
4.57
Opus Genetics Inc stock is traded at $4.57, with a volume of 917.92K.
It is up +7.53% in the last 24 hours and up +99.56% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$4.25
Open:
$4.25
24h Volume:
917.92K
Relative Volume:
1.19
Market Cap:
$315.17M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-4.1927
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
+30.57%
1M Performance:
+99.56%
6M Performance:
+257.03%
1Y Performance:
+357.00%
1-Day Range:
$4.08
$4.59
1-Week Range:
$3.43
$4.59
52-Week Range:
$0.65
$4.59
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.57 | 293.10M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
FDA reviewing NC biotech's treatment for age-related vision loss - The Business Journals
Where Opus Genetics Stands With Analysts - Sahm
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - The Manila Times
Opus Genetics (NASDAQ:IRD) Price Target Raised to $12.00 - MarketBeat
FY2026 EPS Estimates for Opus Genetics Raised by Analyst - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update - MarketBeat
Opus Genetics (NASDAQ:IRD) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Opus Genetics reports early positive data from gene therapy trial - Investing.com South Africa
Opus Genetics (IRD) Shares Promising Gene Therapy Results - GuruFocus
Opus Genetics reports early positive data from gene therapy trial By Investing.com - Investing.com Canada
Opus Genetics Announces Initial Clinical Data from Phase - GlobeNewswire
IRD Should I Buy - Intellectia AI
Opus Genetics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
FDA accepts Opus Genetics’ presbyopia treatment application By Investing.com - Investing.com Australia
FDA accepts sNDA of phentolamine 0.75% for presbyopia - Eyes On Eyecare
FDA accepts Opus Genetics’ presbyopia treatment application - Investing.com Nigeria
Viatris, Opus Genetics Say US FDA Agrees to Review New Drug Application for Potential Eye Condition Treatment - marketscreener.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Reviews Opus Genetics' (IRD) New Eye Treatment for Presbyopi - GuruFocus
Opus Genetics Announces FDA Acceptance Of Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia - TradingView
Eye drops for aging eyes: FDA reviews Opus presbyopia treatment - Stock Titan
Chipmakers Recap: Can Opus Genetics Inc weather a recessionProduct Launch & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 (NASDAQ:IRD) - Seeking Alpha
Aug Patterns: Can Ameresco Inc beat the S P 500Weekly Investment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Opus Genetics (NASDAQ:IRD) Cut to "Sell" at Wall Street Zen - MarketBeat
Opus Genetics (NASDAQ:IRD) Cut to “Sell” at Wall Street Zen - Defense World
Balyasny Asset Management L.P. Acquires Significant Stake in Opu - GuruFocus
Balyasny Asset Management L.P. Acquires Significant Stake in Opus Genetics Inc - GuruFocus
Opus Genetics Closes $25 Million Series B Financing - TipRanks
Opus Genetics Raises $25 Million in Private Placement of Series B Preferred at $3.39 - TradingView
Opus Genetics (NASDAQ: IRD) boosts cash with $25M Series B preferred - Stock Titan
Aug Technicals: Can Fulgent Genetics Inc stock outperform in a bear marketQuarterly Investment Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
MSN Money - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Rating of "Buy" by Brokerages - MarketBeat
Opus Genetics Enters Agreement for $25 Million Private Placement - VisionMonday.com
Opus Genetics Insider Confidence Rewarded, Stock Hits US$233m Market Cap - 富途牛牛
Opus Genetics higher after $25M private placement - MSN
Why Opus Genetics Inc. (R3X1) stock could rally stronglyJuly 2025 Fed Impact & Verified Stock Trade Ideas - mfd.ru
Lifesci Capital Forecasts Opus Genetics FY2025 Earnings - MarketBeat
Can Opus Genetics Inc. reach all time highs this yearWeekly Profit Summary & Weekly Return Optimization Plans - mfd.ru
Is Opus Genetics Inc. stock a good pick for beginnersJuly 2025 Chart Watch & Real-Time Volume Triggers - mfd.ru
Short Interest in Opus Genetics, Inc. (NASDAQ:IRD) Drops By 30.7% - MarketBeat
Aug Sentiment: Is FirstService Corporation stock risky to hold nowMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Opus Genetics raises $25 million in private placement financing By Investing.com - Investing.com Australia
Opus Genetics (NASDAQ:IRD) Raised to Strong-Buy at Lifesci Capital - Defense World
Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding - marketscreener.com
Opus Genetics raises $25 million in private placement financing - Investing.com India
Opus Genetics announces $25 million private placement - marketscreener.com
Opus Genetics Announces $25 Million Private Placement - TradingView
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):